Clinical Trials Logo

Filter by:
NCT ID: NCT01846247 Completed - Stroke Clinical Trials

A Very Early Rehabilitation Trial

AVERT
Start date: June 2006
Phase: N/A
Study type: Interventional

Phase 3, multicenter, international randomized controlled trial of a Very Early Mobilization(VEM) care rehabilitation protocol compared to standard post stroke care (SC). Participants receive either SC and VEM or SC alone in the acute phase of stroke up to a period of 14 days. Participants are followed up by a blinded assessor at 3 and 12 months post stroke to determine trial outcomes.

NCT ID: NCT01846039 Completed - Clinical trials for Asian Nose Enhancement

JUVÉDERM VOLUMA® to Enhance the Appearance of the Asian Nose

Start date: April 1, 2013
Phase: N/A
Study type: Interventional

A prospective, open-label, observational study of the safety and efficacy of JUVÉDERM VOLUMA® to enhance the aesthetic appearance of the Asian nose.

NCT ID: NCT01845311 Completed - Clinical trials for Coronary Artery Disease

ReZolve2 Clinical Investigation

RESTORE II
Start date: April 2013
Phase: N/A
Study type: Interventional

The RESTORE II clinical trial is intended to assess safety and performance of the ReZolve2 Bioresorbable Coronary Scaffold in native coronary arteries.

NCT ID: NCT01843387 Completed - Type 2 Diabetes Clinical Trials

Safety and Efficacy of Mesenchymal Precursor Cells in Diabetic Nephropathy

Start date: July 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The study investigates the safety, tolerability and efficacy of a single intravenous infusion of two doses of mesenchymal precursor cells versus placebo in subjects with diabetic nephropathy and type 2 diabetes.

NCT ID: NCT01842607 Completed - Asthma Clinical Trials

A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects

Start date: May 27, 2013
Phase: Phase 3
Study type: Interventional

This is a multi-centre, open-label long-term safety study of 100 milligram (mg) mepolizumab administered subcutaneously (SC) every 4 weeks for 12 months in addition to standard of care in subjects who have severe, refractory asthma and a history of eosinophilic inflammation. Subjects who completed either MEA115588 or MEA115575 will be offered the opportunity to consent for this study.

NCT ID: NCT01840410 Completed - Clinical trials for Choroidal Neovascularization (CNV)

Assess the Efficacy/Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Choroidal Neovascularization.

Start date: September 2013
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy and safety of 0.5 mg in adult patients with visual impairment due to choridal neovascularization (CNV).

NCT ID: NCT01839760 Completed - Influenza Clinical Trials

Evaluation of Viral Shedding Patterns and Clinical Outcomes of Influenza Patients

Start date: December 2012
Phase: N/A
Study type: Observational

The objective of the study is virological assessment (e.g., proportion of prolonged viral shedding, median days to viral clearance, and viral load) in laboratory-confirmed adult influenza patients admitted to the general ward and/or to the ICU and to assess the correlation with the clinical manifestations and prognosis.

NCT ID: NCT01839149 Completed - Clinical trials for High Frequency Episodic Migraine and Chronic Migraine

TI-001 (Intranasal Oxytocin) for Treatment of High Frequency Episodic Migraine and Chronic Migraine

Start date: May 2013
Phase: Phase 2
Study type: Interventional

This study evaluates the use of oxytocin, given as a nasal spray, for treatment of high frequency episodic migraine and chronic migraine.

NCT ID: NCT01837251 Completed - Clinical trials for Recurrent Platinum-sensitive Ovarian Cancer

Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer

Start date: May 2013
Phase: Phase 3
Study type: Interventional

Evaluation of the best therapeutic index for patients with platinum-sensitive ovarian cancer when treatment with bevacizumab and gemcitabine/carboplatin or with bevacizumab and PLD/carboplatin.

NCT ID: NCT01836523 Completed - Diabetes Clinical Trials

The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes

ADJUNCT ONEā„¢
Start date: November 2013
Phase: Phase 3
Study type: Interventional

This trial is conducted globally. The aim of the trial is to confirm the efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetes. The total trial duration per subject is approximately 58 weeks.